Diabetes-induced impairment in visual function in mice: Contributions of p38 MAPK, RAGE, leukocytes, and aldose reductase

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 5, 2013, Pages 2904-2910

  Lee, Chieh Allen ^a   Li, Guangyuan ^a,b   Patel, Mansi D ^c   Mark Petrash, J ^d   Benetz, Beth Ann ^e   Veenstra, Alex ^a   Amengual, Jaume ^a   von Lintig, Johannes ^a   Burant, Christopher J ^a,f   Tang, Johnny ^a,e,f   Kern, Timothy S ^a,f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c St Louis School of Medicine   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Contrast senstivity; Diabetic retinopathy; Spatial frequency threshold

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDEHYDE REDUCTASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHA 666859; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CATARACT; CONTRAST SENSITIVITY; DIABETES MELLITUS; HYPERGLYCEMIA; HYPERPHAGIA; LEUKOCYTE; MALE; MOUSE; NONHUMAN; OPTOKINETIC STIMULATION; PERCEPTION; PHOTOGRAPHY; POLYURIA; PRIORITY JOURNAL; PUPIL; RETINA; SPATIAL ANALYSIS; SPATIAL FREQUENCY THRESHOLD; VASCULAR LESION; VISION; VISUAL ACUITY;

CONTRAST SENSTIVITY; DIABETIC RETINOPATHY; SPATIAL FREQUENCY THRESHOLD;

ALDEHYDE REDUCTASE; ANALYSIS OF VARIANCE; ANIMALS; CONTRAST SENSITIVITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; LEUKOCYTES; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PSYCHOPHYSICS; RECEPTORS, IMMUNOLOGIC; SENSORY THRESHOLDS; SPACE PERCEPTION;

EID: 84899768544     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11659     Document Type: Article

References (68)

1. Bresnick GH, Korth K, Groo A, Palta M. Electroretinographic oscillatory potentials predict progression of diabetic retinopathy. Preliminary report. Arch Ophthalmol. 1984;102:1307-1311.
2. Bresnick GH, Palta M. Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol. 1987;105:929-933.
3. Holopigian K, Seiple W, Lorenzo M, Carr R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1992;33: 2773-2780.
4. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40:2638-2651.
5. Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol. 1999;44:53-60.
6. Tyrberg M, Ponjavic V, Lövestam-Adrian M. Multifocal electroretinogram (mfERG) in patients with diabetes mellitus and an enlarged foveal avascular zone (FAZ). Doc Ophthalmol. 2008; 117:185-189.
7. Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology. 1988;95:1340-1348.
8. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998-1003.
9. Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221-2230.
10. Ewing FM, Deary IJ, Strachan MW, Frier BM. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev. 1998; 19:462-476.
11. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1-9.
12. Mones J, Rubin GS. Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye (Lond). 2005;19:1142-1150.
13. Lord SR, Clark RD, Webster IW. Visual acuity and contrast sensitivity in relation to falls in an elderly population. Age Ageing. 1991;20:175-181.
14. Tang Y, Zhou Y. Age-related decline of contrast sensitivity for second-order stimuli: earlier onset, but slower progression, than for first-order stimuli. J Vis. 2009;9:18.
15. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343-358.
16. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2007;48:5152-5159.
17. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylatebased anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007;56:337-345.
18. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol. 2008;586:4401-4408.
19. Smith SB, Duplantier JN, Dun Y, et al. In vivo protection against retinal neurodegeneration by the {sigma}R1 ligand (+)-pentazocine. Invest Ophthalmol Vis Sci. 2008;49:4154-4161.
20. Kim YH, Kim YS, Kang SS, Cho GJ, Choi WS. Resveratrol inhibits neuronal apoptosis and elevated Ca2+/calmodulindependent protein kinase II activity in diabetic mouse retina. Diabetes. 2010;59:1825-1835.
21. Fan J, Xu G, Jiang T, Qin Y. Pharmacologic induction of heme oxygenase-1 plays a protective role in diabetic retinopathy in rats. Invest Ophthalmol Vis Sci. 2012;53:6541-6556.
22. Du Y, Tang J, Li G, et al. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci. 2010;51:2158-2164.
23. Li G, Tang J, Du Y, Lee CA, Kern TS. Beneficial effects of RAGEIg fusion protein on early diabetic retinopathy and tactile allodynia. Mol Vis. 2011;17:3156-3165.
24. Kandpal RP, Rajasimha HK, Brooks MJ, et al. Transcriptome analysis using next generation sequencing reveals molecular signatures of diabetic retinopathy and efficacy of candidate drugs. Mol Vis. 2012;18:1123-1146.
25. Ho HT, Chung SK, Law JW, et al. Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol Cell Biol. 2000;20:5840-5846.
26. Talahalli R, Zarini S, Tang J, et al. Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. J Leukoc Biol. 2012;93:135-143.
27. Li G, Veenstra AA, Talahalli RR, et al. Marrow-derived cells regulate the development of early diabetic retinopathy and tactile allodynia in mice. Diabetes. 2012;61:3294-3303.
28. Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci. 2004;45:4611-4616.
29. Prusky GT, Douglas RM. Characterization of mouse cortical spatial vision. Vision Res. 2004;44:3411-3418.
30. Chylack LT Jr, Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol. 1993;111:831-836.
31. Ghafour IM, Foulds WS, Allan D, McClure E. Contrast sensitivity in diabetic subjects with and without retinopathy. Br J Ophthalmol. 1982;66:492-495.
32. Della Sala S, Bertoni G, Somazzi L, Stubbe F, Wilkins AJ. Impaired contrast sensitivity in diabetic patients with and without retinopathy: a new technique for rapid assessment. Br J Ophthalmol. 1985;69:136-142.
33. Banford D, North RV, Dolben J, Butler G, Owens DR. Longitudinal study of visual functions in young insulin dependent diabetics. Ophthalmic Physiol Opt. 1994;14:339-346.
34. Verrotti A, Lobefalo L, Petitti MT, et al. Relationship between contrast sensitivity and metabolic control in diabetics with and without retinopathy. Ann Med. 1998;30:369-374.
35. Sokol S, Moskowitz A, Skarf B, Evans R, Molitch M, Senior B. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol. 1985;103:51-54.
36. Trick GL, Burde RM, Gordon MO, Santiago JV, Kilo C. The relationship between hue discrimination and contrast sensitivity deficits in patients with diabetes mellitus. Ophthalmology. 1988;95:693-698.
37. Di Leo MA, Caputo S, Falsini B, et al. Nonselective loss of contrast sensitivity in visual system testing in early type I diabetes. Diabetes Care. 1992;15:620-625.
38. Juen S, Kieselbach GF. Electrophysiological changes in juvenile diabetics without retinopathy. Arch Ophthalmol. 1990;108: 372-375.
39. Liska V, Dostalek M. Are contrast sensitivity functions impaired in insulin dependent diabetics without diabetic retinopathy? Acta Medica (Hradec Kralove). 1999;42:133-138.
40. Brinchmann-Hansen O, Bangstad HJ, Hultgren S, et al. Psychophysical visual function, retinopathy, and glycemic control in insulin-dependent diabetics with normal visual acuity. Acta Ophthalmol (Copenh). 1993;71:230-237.
41. Akimov NP, Renteria RC. Spatial frequency threshold and contrast sensitivity of an optomotor behavior are impaired in the Ins2Akita mouse model of diabetes. Behav Brain Res. 2012;226:601-605.
42. Owsley C, Sekuler R, Siemsen D. Contrast sensitivity throughout adulthood. Vision Res. 1983;23:689-699.
43. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188-2197.
44. Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabeticmacular edema. Invest Ophthalmol Vis Sci. 2005;46:3855-3858.
45. Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221-2230.
46. Davis MD, Sheetz MJ, Aiello LP, et al. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50:1-4.
47. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46:2210-2218.
48. Feit-Leichman RA, Kinouchi R, Takeda M, et al. Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Invest Ophthalmol Vis Sci. 2005; 46:4281-4287.
49. Zheng L, Du Y, Miller C, et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia. 2007;50: 1987-1996.
50. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci. 2004;45:3330-3336.
51. Smith SB, Duplantier J, Dun Y, et al. In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine. Invest Ophthalmol Vis Sci. 2008;49:4154-4161.
52. Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia. 2010;53:971-979.
53. Zhu SS, Ren Y, Zhang M, et al. Wld(S) protects against peripheral neuropathy and retinopathy in an experimental model of diabetes in mice. Diabetologia. 2011;54:2440-2450.
54. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes. 2003;52:506-511.
55. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS. 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes. 2008;57:1387-1393.
56. Berkowitz BA, Gradianu M, Bissig D, Kern TS, Roberts R. Retinal ion regulation in a mouse model of diabetic retinopathy: natural history and the effect of Cu/Zn superoxide dismutase overexpression. Invest Ophthalmol Vis Sci. 2009;50:2351-2358.
57. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9:14-36.
58. Hotta N, Koh N, Sakakibara F, et al. Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats. Eur J Pharmacol. 1997;326: 45-51.
59. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci. 2003;44:3135-3143.
60. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52:864-871.
61. Cheung AK, Fung MK, Lo AC, et al. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005;54:3119-3125.
62. Tang J, Du Y, Petrash JM, Sheibani N, Kern TS. Deletion of aldose reductase from mice inhibits diabetes-induced retinal capillary degeneration and superoxide generation. PLoS One. 2013;8:e62081.
63. Samuels IS, Lee CA, Petrash JM, Peachey NS, Kern TS. Exclusion of aldose reductase as a mediator of ERG deficits in a mouse model of diabetic eye disease. Vis Neurosci. 2012; 29:267-274.
64. Ludvigson MA, Sorenson RL. Immunohistochemical localization of aldose reductase II. Rat eye and kidney. Diabetes. 1980; 29:450-459.
65. Kern TS, Engerman RL. Distribution of aldose reductase in ocular tissue. Exp Eye Res. 1981;33:175-182.
66. Chakrabarti S, Sima AA, Nakajima T, Yagihashi S, Greene DA. Aldose reductase in the BB rat: isolation, immunological identification and localization in the retina and peripheral nerve. Diabetologia. 1987;30:244-251.
67. Hegde KR, Henein MG, Varma SD. Establishment of the mouse as a model animal for the study of diabetic cataracts. Ophthalmic Res. 2003;35:12-18.
68. Varma SD, Kinoshita JH. The absence of cataracts in mice with congenital hyperglycemia. Exp Eye Res. 1974;19:577-582.